Sexual wellness
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. · Int J Impot Res · 2004
PMID: 14963471 · DOI: 10.1038/sj.ijir.3901167
Summary
Double-blind placebo-controlled study of intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction. Endpoints: safety, plasma PK, RigiScan-measured erectile response.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →PT-141Cyclic heptapeptide melanocortin agonist studied in libido and sexual-physiology research.
Guides covering this compound
More Sexual wellness citations
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsObstet Gynecol · 2019
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderObstet Gynecol · 2019
- Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to ViagraInt J Impot Res · 2004